Discovery of Casdatifan, Part II: A Potent and Orally Bioavailable Inhibitor of Hypoxia Inducible Factor-2α.
Artur K Mailyan, Guillaume Mata, Joel W Beatty...
https://pubmed.ncbi.nlm.nih.gov/42246926/Actively Recruiting
Led by Arcus Biosciences, Inc. · Updated on 2026-11-02
720
Participants Needed
191
Research Sites
139 weeks
Total Duration
Researchers are evaluating whether casdatifan combined with cabozantinib can improve progression-free survival compared to placebo plus cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma. The study focuses on patients who have previously received anti-PD-1 or anti-PD-L1 therapies in their most recent treatment, with no more than one prior metastatic treatment regimen. This is a randomized, double-blind, active-controlled phase 3 trial aimed at advancing treatment options for this patient group. Participants will be randomly assigned to receive either casdatifan and cabozantinib or placebo and cabozantinib, both taken orally. The study includes two treatment arms one experimental arm with casdatifan and cabozantinib, and a comparator arm with placebo and cabozantinib. Treatment is ongoing, with monitoring for up to approximately 33 months for key outcomes, and follow-up for overall survival up to about 64 months. Throughout the study, participants will undergo regular assessments including imaging scans evaluated by a blinded independent review to measure tumor response and progression. Researchers will track progression-free survival, overall survival, response rates, duration of response, disease control, and treatment-related adverse events. Symptom changes will also be monitored using patient-reported measures. The total participation duration may extend up to several years to capture long-term outcomes and safety data.
CONDITIONS
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
M
Medical Director
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Arcus Biosciences, Inc.
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Casdatifan + Cabozantinib | Placebo + Cabozantinib | Cabozantinib alone |
|---|---|---|---|
| What it is | An investigational combination of casdatifan (a HIF‑2α inhibitor) plus cabozantinib being evaluated as a randomized treatment arm. | A trial control arm using placebo plus cabozantinib. | Cabozantinib monotherapy is a current standard systemic treatment option for metastatic clear cell renal cell carcinoma. |
| Role in trial | Investigational experimental arm. | Placebo-controlled comparator arm. | Not part of the trial; shown for reference to current clinical practice. |
| Primary use | Being studied as a systemic therapy for advanced clear cell RCC. | Reference control to measure casdatifan add‑on effect. | Used in clinical practice as a monotherapy systemic treatment for metastatic clear cell RCC. |
| How administered | Oral casdatifan combined with oral cabozantinib as per trial protocol. | Oral cabozantinib plus matching oral placebo. | Oral cabozantinib, dosed per approved clinical use. |
| Evidence status | Efficacy is under evaluation; trial in progress. | Serves as control to measure investigational effect. | Supported by existing clinical practice and guideline-based preference. |
| Important limitations | Effectiveness and safety are unknown until trial results are available. | This arm serves only as a comparator and does not reflect current standard monotherapy. | This is not tested within the trial and may differ in efficacy when combined versus alone. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to approximately 33 months
Participants receive either casdatifan with cabozantinib or placebo with cabozantinib, taken orally as part of the study treatment.
Regular visits for monitoring and assessments
Duration - Up to approximately 64 months
Participants are monitored for overall survival and long-term safety after treatment ends.
Periodic follow-up visits
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Artur K Mailyan, Guillaume Mata, Joel W Beatty...
https://pubmed.ncbi.nlm.nih.gov/42246926/Arcus Biosciences, Inc.
Lead Sponsor